EP 3 400 943 B1 results from a divisional application of EP 2 827 900 published as WO 2013/142875, and relates to an amorphous solid dispersion for use in the treatment of local or metastatic brain cancer that is caused by ErbB2 over-expression or amplification.
Brief outline of the case
Both oppositions were rejected and both opponents appealed.